DocuSign (DOCU) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 May, 2026Board of directors and corporate governance
Rowan Trollope appointed as a Class III independent director, effective May 2, 2026, with a term expiring at the 2027 Annual Meeting of Stockholders.
Trollope brings extensive experience as a CEO and board member in enterprise software and technology sectors.
Appointment followed recommendation by the Nominating and Corporate Governance Committee.
Trollope will receive compensation per the Amended and Restated Director Compensation Program.
Trollope will enter into the standard indemnity agreement for directors.
Executive compensation and say-on-pay
Director compensation for Trollope will follow the existing Director Compensation Program as disclosed in prior SEC filings.
Related party transactions
No direct or indirect material interest or arrangement exists between Trollope and any other person regarding his selection as director.
Latest events from DocuSign
- Performance-based pay, board refreshment, and strong investor engagement drive governance.DOCU
Proxy filing7 May 2026 - Record margins, robust cash flow, and IAM-driven growth set the stage for further expansion.DOCU
Q4 20263 May 2026 - Proxy details governance, compensation reforms, and key votes, with Board opposing ESG risk report.DOCU
Proxy filing16 Apr 2026 - Q1 revenue up 7%, IAM platform launched, and $1B added to share repurchase program.DOCU
Q1 20251 Feb 2026 - Revenue up 7% to $736M, record margin, $888M net income, and IAM platform launch.DOCU
Q2 202522 Jan 2026 - Q3 revenue up 8% to $755M, with strong billings, IAM adoption, and international growth.DOCU
Q3 202511 Jan 2026 - IAM growth, AI integration, and financial discipline drive scalable, durable expansion.DOCU
53rd Annual Nasdaq Investor Conference6 Jan 2026 - IAM adoption accelerates with 10,000 customers, premium pricing, and a scalable go-to-market model.DOCU
Momentum Investor Session21 Dec 2025 - Q3 delivered 8% revenue growth, 10% billings growth, and record buybacks with strong IAM momentum.DOCU
Q3 20267 Dec 2025